Key terms
About ACRV
Acrivon Therapeutics, Inc. develops drugs for clinical treatment. Its unique precision medicine platform is Acrivon Predictive Precision Proteomics (AP3). AP3 is used to generate proprietary OncoSignature companion diagnostics to identify patients who will benefit from the medicine. The company was founded by Peter Blume-Jensen and Kristina Masson in 2018 and is headquartered in Watertown, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ACRV news
Apr 09
11:15am ET
Acrivon Therapeutics: Strategic Finance and Clinical Promise Merit a Buy Rating
Apr 09
7:22am ET
Acrivon Therapeutics Secures $130M for Drug Development Expansion
Apr 05
9:03am ET
Ladenburg ‘more suspicious’ about Acrivon upcoming data, cuts target
Apr 02
3:40pm ET
Analysts Are Bullish on These Healthcare Stocks: Acrivon Therapeutics, Inc. (ACRV), Abivax SA Sponsored ADR (ABVX)
Apr 01
12:25am ET
Buy Rating on Acrivon Therapeutics: Anticipated Clinical Validation and Strong Financial Position
Mar 28
3:55pm ET
Buy Rating Affirmed for Acrivon Therapeutics Amid Anticipated Clinical Updates and Platform Potential
Mar 28
2:07pm ET
Acrivon Therapeutics: Strong Buy on Promising Clinical Trials and Innovative Drug Development
Mar 28
12:42pm ET
Acrivon Therapeutics price target lowered to $21 from $25 at Oppenheimer
Mar 28
11:55am ET
Buy Rating Justified by Acrivon Therapeutics’ Clinical Progress and Market Potential
Mar 28
8:01am ET
Acrivon Therapeutics reports Q4 EPS (86c), consensus (73c)
Mar 04
8:05am ET
Acrivon Therapeutics appoints Santhosh Palani to board of directors
Mar 01
4:47am ET
Acrivon Therapeutics initiated with an Outperform at JMP Securities
Mar 01
12:25am ET
Unlocking Value in Precision Oncology: Acrivon Therapeutics’ Unique Platform and Promising Pipeline
Feb 09
4:19am ET
Acrivon Therapeutics Welcomes New Board Member Dr. Magovcevic-Liebisch
Feb 08
8:15am ET
Acrivon Therapeutics appoints Magovcevic to board of directors
Jan 12
7:15am ET
Acrivon Therapeutics: A Buy Rating on Revolutionary Precision Medicine Platform and Promising Clinical Trials
No recent press releases are available for ACRV
ACRV Financials
Key terms
Ad Feedback
ACRV Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ACRV Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range